GLAXOSMITHKLINE PHARMACEUTICALS
|
|
| BOM : 500660 NSE : GLAXO | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Jun 24,2022 |
|
Price(EOD): ₹ 1,499.75
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 25,405.77 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAXOSMITHKLINE PHARMACEUTICALS | -0.5% | -0.9% | -0.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.4% | -8.5% | 23.8% |
| DIVIS LABORATORIES | 4.3% | 6.7% | -12.6% |
| DR REDDYS LABORATORIES | 3.8% | 0% | -18.7% |
| CIPLA | 0.8% | -3.2% | -2.4% |
| GLAND PHARMA | 2.4% | -7.3% | -17.9% |
| PIRAMAL ENTERPRISES | 3.9% | -11% | -33.4% |
| CADILA HEALTHCARE | 5.7% | -5.1% | -45.1% |
| TORRENT PHARMACEUTICALS | 4.1% | -0.9% | -2.5% |
FUNDAMENTAL ANALYSIS OF GLAXOSMITHKLINE PHARMACEUTICALS
[ Q(TTM): Mar2022, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLAXOSMITHKLINE PHARMACEUTICALS
[As on : Jun 24,2022
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
70.94
P/E Calculated based on EPS of 21.14
[ Mar2021 - Consolidated Results ] 16.95
P/B Calculated based on Book Value of 88.49
[ Mar2021 - Consolidated Results ] 7.42
P/S Calculated based on Revenues of 3425.41 Cr
[ TTM - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
22% 2% -2% |
SHARE PRICE MOMENTUM OF GLAXOSMITHKLINE PHARMACEUTICALS
GLAXOSMITHKLINE PHARMACEUTICALS vs SENSEX
DEBT OF GLAXOSMITHKLINE PHARMACEUTICALS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2022 2021 2020 Avg_3yrs |
0 0 0 - |
- 0 0 - |
|
[Last Annual Data : Mar2021]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF GLAXOSMITHKLINE PHARMACEUTICALS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2022 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF GLAXOSMITHKLINE PHARMACEUTICALS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-0.77% -11.42% 21.01% -139.53% |
8.76% 11.83% 324.44% -1597.53% |
| QtrlyTrend |
0 | |
| Latest Qtr: Mar2022 | ||
| Quarterly Result Analysis → | ||
GLAXOSMITHKLINE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3.1% | -1.8% | -13% |
| S&P BSE LOW VOLATILITY | 2.9% | -1.3% | -7.6% |
| S&P BSE 200 | 2.6% | -1.9% | -0.7% |
| S&P BSE LARGE MIDCAP | 2.6% | -1.9% | -0.7% |
| S&P BSE 250 LARGEMIDCAP | 2.5% | -2% | -0.8% |
| S&P BSE 500 | 2.5% | -2% | -1% |
| S&P BSE ALLCAP | 2.5% | -2% | -0.8% |
| S&P BSE MID CAP | 2.4% | -0.1% | -2.8% |
| S&P BSE 150 MIDCAP | 2.1% | -1.2% | -0.9% |
| S&P BSE 400 MIDSMALLCAP | 2% | -1.6% | -1.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MNC | 3.3% | -1% | 1.3% |
| NIFTY 500 | 2.5% | -2% | -1% |
| NIFTY LARGE MIDCAP 250 | 2.4% | -1.7% | -0.8% |
| NIFTY500 MULTICAP 50:25:25 | 2.3% | -2% | -1.3% |
| NIFTY MIDCAP150 | 2.1% | -1.4% | -0.9% |
| NIFTY MID SMALL400 | 2% | -1.7% | -1.6% |
| NIFTY MIDCAP150 QUALITY 50 | 0.9% | -0.9% | -5.2% |
You may also like the below Video Courses
FAQ about GLAXOSMITHKLINE PHARMACEUTICALS
Is GLAXOSMITHKLINE PHARMACEUTICALS good for long term investment?
As on Jun 24,2022, the Fundamentals of GLAXOSMITHKLINE PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of GLAXOSMITHKLINE PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLAXOSMITHKLINE PHARMACEUTICALS UnderValued or OverValued?
As on Jun 24,2022, GLAXOSMITHKLINE PHARMACEUTICALS is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS ?
As on Jun 24,2022, the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS is Rs. 1,465.09 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,228.07
Fair Value [Median EV / Sales Model] : Rs. 1,465.09
Fair Value [Median Price / Sales Model] : Rs. 1,536.36
Median Fair Value of GLAXOSMITHKLINE PHARMACEUTICALS : Rs. 1,465.09
Is GLAXOSMITHKLINE PHARMACEUTICALS trading at a Premium or Discount?
As on Jun 24,2022, GLAXOSMITHKLINE PHARMACEUTICALS is trading at a Premium of 2% based on the estimates of Median Intrinsic Value!
Check out Annual Financials of Industry Peers
Check out Quarterly Results of Industry Peers
Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].
